Compile Data Set for Download or QSAR
Report error Found 86 Enz. Inhib. hit(s) with all data for entry = 2574
TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372206(US10239882, Example 76)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372196(US10239882, Example 54)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372197(US10239882, Example 55)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372198(US10239882, Example 59)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372199(US10239882, Example 60)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372200(US10239882, Example 61)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372201(US10239882, Example 62)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372202(US10239882, Example 66)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372203(US10239882, Example 67)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372204(US10239882, Example 72)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372205(US10239882, Example 74)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372175(US10239882, Example 15)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372207(US10239882, Example 78)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372208(US10239882, Example 79)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372209(US10239882, Example 80)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372210(US10239882, Example 81)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372211(US10239882, Example 82)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372212(US10239882, Example 83)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372213(US10239882, Example 84)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372214(US10239882, Example 85)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372174(US10239882, Example 13)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372194(US10239882, Example 52)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372176(US10239882, Example 17)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372177(US10239882, Example 19)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372178(US10239882, Example 20)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372179(US10239882, Example 21)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372180(US10239882, Example 23)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372181(US10239882, Example 25)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372182(US10239882, Example 29)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372183(US10239882, Example 30)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372184(US10239882, Example 31)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372186(US10239882, Example 37)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372185(US10239882, Example 36)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372195(US10239882, Example 53)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372193(US10239882, Example 50)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372192(US10239882, Example 46)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372191(US10239882, Example 42)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372190(US10239882, Example 41)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372189(US10239882, Example 40)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372188(US10239882, Example 39)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372187(US10239882, Example 38)
Affinity DataIC50: 100nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372234(US10239882, Example 45)
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372235(US10239882, Example 47)
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372236(US10239882, Example 48)
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372237(US10239882, Example 49)
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372238(US10239882, Example 51)
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372239(US10239882, Example 56)
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372240(US10239882, Example 57)
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372241(US10239882, Example 58)
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

TargetcGMP-dependent 3',5'-cyclic phosphodiesterase(Human)
Dart Neuroscience (Cayman)

US Patent
LigandPNGBDBM372242(US10239882, Example 63)
Affinity DataIC50: 550nMAssay Description:An IMAP TR-FRET-based phosphodiesterase assay was developed using the PDE2A isoform. IMAP technology is based on high-affinity binding of phosphate b...More data for this Ligand-Target Pair
In Depth
Date in BDB:
12/30/2019
Entry Details
Go to US Patent

Displayed 1 to 50 (of 86 total ) | Next | Last >>
Jump to: